Lisdexamfetamine Dimesylate Patent Expiration

Lisdexamfetamine Dimesylate is Used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Vyvanse on Feb 23, 2007. Another drug containing Lisdexamfetamine Dimesylate is Arynta. 20 different companies have introduced drugs containing Lisdexamfetamine Dimesylate.


Lisdexamfetamine Dimesylate Patents

Given below is the list of patents protecting Lisdexamfetamine Dimesylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Arynta US11576878 Oral solutions comprising lisdexamfetamine salts Aug 30, 2040 Azurity
Vyvanse US7105486

(Pediatric)

Abuse-resistant amphetamine compounds Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7223735

(Pediatric)

Abuse resistant lysine amphetamine compounds Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7655630

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659253

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659254

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662787

(Pediatric)

Abuse resistant lysine amphetamine compounds Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662788

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671030

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671031

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7674774

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678770

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678771

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687466

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687467

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7700561

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7713936

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7718619

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7723305

(Pediatric)

Abuse-resistant amphetamine prodrugs Aug 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7105486 Abuse-resistant amphetamine compounds Jun 29, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7223735 Abuse resistant lysine amphetamine compounds Jun 29, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7700561 Abuse-resistant amphetamine prodrugs Jun 29, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687467 Abuse-resistant amphetamine prodrugs Apr 08, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678770 Abuse-resistant amphetamine prodrugs Mar 25, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678771 Abuse-resistant amphetamine prodrugs Mar 25, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7674774 Abuse-resistant amphetamine prodrugs Mar 18, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671031 Abuse-resistant amphetamine prodrugs Feb 28, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7105486 Abuse-resistant amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7223735 Abuse resistant lysine amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7655630 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7655630 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659253 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659253 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7659254 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662787 Abuse resistant lysine amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662787 Abuse resistant lysine amphetamine compounds Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7662788 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671030 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7671031 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7674774 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678770 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7678771 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687466 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7687467 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7700561 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7713936 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7718619 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa
Vyvanse US7723305 Abuse-resistant amphetamine prodrugs Feb 24, 2023

(Expired)

Takeda Pharms Usa



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lisdexamfetamine Dimesylate's patents.

Given below is the list recent legal activities going on the following patents of Lisdexamfetamine Dimesylate.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 21 Oct, 2021 US7718619(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 21 Oct, 2021 US7713936
Payment of Maintenance Fee, 12th Year, Large Entity 21 Oct, 2021 US7723305(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 24 Sep, 2021 US7700561(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Aug, 2021 US7674774(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Aug, 2021 US7687466(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Aug, 2021 US7678770(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Aug, 2021 US7671031(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Aug, 2021 US7671030(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Aug, 2021 US7678771(Litigated)


Lisdexamfetamine Dimesylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Lisdexamfetamine Dimesylate Generic API Manufacturers

Several generic applications have been filed for Lisdexamfetamine Dimesylate. The first generic version for Lisdexamfetamine Dimesylate was by Hikma Pharmaceuticals Usa Inc and was approved on Aug 25, 2023. And the latest generic version is by Granules Pharmaceuticals Inc and was approved on Jan 29, 2025.

Given below is the list of companies who have filed for Lisdexamfetamine Dimesylate generic, along with the locations of their manufacturing plants worldwide.